Adaptimmune Therapeutics, which is developing cancer immunotherapies using genetically enhanced T-cell receptors, raised $191 million by offering 11.3 million shares at $17, at high end of the $15-$17 range. At its offer price, Adaptimmune Therapeutics will command a fully diluted market cap at $1.3 billion. The company will list on the NASDAQ under the symbol ADAP. BofA Merrill Lynch, Cowen & Company and Leerink Partners acted as lead managers on the deal.
